The mission of the UCSF-GIVI CFAR is to promote multidisciplinary research at the intersection of the basic, clinical and behavioral-epidemiological sciences with the goal of ending the global HIV epidemic. To fulfill its mission, CFAR collaborates with UCSF's Center for AIDS Prevention Studies (CAPS) to coordinate a multi-pronged program that includes: 1) providing scientific leadership and direction through a proactive planning process that identifies the most important challenges emerging at the leading edge of HIV research;2) assembling research teams across different disciplines and sites to address all dimensions of these identified challenges;3) maintaining an outstanding set of scientific cores that extends the scientific reach of Center investigators;4) ensuring a highly skilled, ethnically diverse, and thoughtful next generation of HIV investigators by providing a strong mentoring and pilot grants program unique at UCSF;5) directing CFAR's research and capacity building programs to international sites where the epidemic is hitting the hardest;6) engaging the communities we serve through a set of novel alliances involving Project Inform, the Forum for Collaborative HIV Research, and UCSF's Science and Health Education Partnership and 7) ensuring our programs are closely aligned with the NIH's AIDS programs, OAR's strategic plan for HIV/AIDS, and the President's National Strategy for HIV/AIDS. CFAR brings value by creafing and sustaining a true community of HIV/AIDS science. CFAR seeks transparency, discipline and inclusiveness in all of its operations and programs. CFAR is proud of its accomplishments in the last four years including publication of 1,172 papers, the mentoring of 44 early career investigators, the award of $4.1 million in CFAR grants and supplements to 85 scientists, the success of CFAR investigators in winning $135 million dollars in peer-reviewed, HIV related funding, and the planning and organization of the first Sub-Saharan Africa CFAR Conference that featured the work of African scientists from 13 countries and will help to build effective South-South collaborations. However, much work remains to be done. CFAR looks forward to helping stimulate progress on multiple scientific fronts including HIV and Aging, HIV eradication, increasing access to proven biomedical approaches to HIV prevention including chemoprophylaxis and reducing community viral load, and addressing disparities in HIV care and treatment within resource-limited communities in the Bay Area and abroad.

Public Health Relevance

The UCSF-GIVI CFAR is dedicated to promoting multidisciplinary research to accelerate progress in answering the important questions emerging in HIV/AIDS biology, treatment, and preven2ion. This approach has led to breakthrough discoveries advancing patient care and providing new approaches for curbing HIV infection in the United States and at international sites. CFAR is also committed to identifying and supporting the next generation of HIV investigators who are critical for truly ending the HIV epidemic.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-RRS-A (J1))
Program Officer
Namkung, Ann S
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
Internal Medicine/Medicine
Schools of Medicine
San Francisco
United States
Zip Code
Mmeje, Okeoma; van der Poel, Sheryl; Workneh, Meklit et al. (2015) Achieving pregnancy safely: perspectives on timed vaginal insemination among HIV-serodiscordant couples and health-care providers in Kisumu, Kenya. AIDS Care 27:6-Oct
Edwards, Jessie K; Cole, Stephen R; Adimora, Adaora et al. (2015) Illustration of a measure to combine viral suppression and viral rebound in studies of HIV therapy. J Acquir Immune Defic Syndr 68:241-4
Chan, Brian T; Weiser, Sheri D; Boum, Yap et al. (2015) Persistent HIV-related stigma in rural Uganda during a period of increasing HIV incidence despite treatment expansion. AIDS 29:83-90
Chan, Brian T; Weiser, Sheri D; Boum, Yap et al. (2015) Declining prevalence of probable depression among patients presenting for antiretroviral therapy in rural Uganda: the role of early treatment initiation. AIDS Behav 19:19-26
Psaros, Christina; Haberer, Jessica E; Boum 2nd, Yap et al. (2015) The factor structure and presentation of depression among HIV-positive adults in Uganda. AIDS Behav 19:27-33
Jagannathan, Prasanna; Eccles-James, Ijeoma; Bowen, Katherine et al. (2014) IFN?/IL-10 co-producing cells dominate the CD4 response to malaria in highly exposed children. PLoS Pathog 10:e1003864
Dworkin, Shari L; Lu, Tiffany; Grabe, Shelly et al. (2014) What community-level strategies are needed to secure women's property rights in Western Kenya? Laying the groundwork for a future structural HIV prevention intervention. AIDS Care 26:754-7
Liu, Albert Y; Yang, Qiyun; Huang, Yong et al. (2014) Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP). PLoS One 9:e83736
Martinez, Priscilla; Tsai, Alexander C; Muzoora, Conrad et al. (2014) Reversal of the Kynurenine pathway of tryptophan catabolism may improve depression in ART-treated HIV-infected Ugandans. J Acquir Immune Defic Syndr 65:456-62
Rebeiro, Peter F; Horberg, Michael A; Gange, Stephen J et al. (2014) Strong agreement of nationally recommended retention measures from the Institute of Medicine and Department of Health and Human Services. PLoS One 9:e111772

Showing the most recent 10 out of 355 publications